Company Overview and News

Stop missing out on important events!

Fintel provides real time notifications of important company events such as major investments (13D/G filings), insider trades (SEC form 4), and important SEC filings. Sign up and create your company alerts for free.

Headline News

ATOS / Atossa Genetics Inc 8-K (Current Report)

2018-02-21 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934   Date of Report (Date of Earliest Event Reported): February 21, 2018   Atossa Genetics Inc. (Exact name of registrant as specified in its charter)           Delaware   001-35610   26-4753208 (State or other jurisdiction of incorporation)   (Commission File Number)   (I. (195-0)

ATOS / Atossa Genetics Inc / Iroquois Capital Management, LLC - 3G/A (Passive Investment)

2018-02-16 sec.gov
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549   SCHEDULE 13G   (Rule 13d-102)   INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2.   (Amendment No. 1)*   Atossa Genetics Inc. (Name of Issuer)   Common Stock, $0.015 par value per share (Title of Class of Securities)   04962H209 (CUSIP Number)   December 31, 2017 (Date of Event Which Requires Filing of this Statement)   Check the appropriate box t

ATOS / Atossa Genetics Inc / Iroquois Capital Management, LLC - 3G/A (Passive Investment)

2018-02-16 sec.gov
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549   SCHEDULE 13G   (Rule 13d-102)   INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2.   (Amendment No. 1)*   Atossa Genetics Inc. (Name of Issuer)   Common Stock, $0.015 par value per share (Title of Class of Securities)   04962H209 (CUSIP Number)   December 31, 2017 (Date of Event Which Requires Filing of this Statement)   Check the appropriate box t

Atossa Genetic's Janet Rea Presenting On ''TRAP CAR-T and Related Cell Therapies'' at Adoptive T- Cell Therapy Symposium In San Francisco Feb. 15th

2018-02-14 accesswire
SAN FRANCISCO, CA / ACCESSWIRE / February 14, 2018 / Janet Rea, MSPH, RAC, Senior Vice President of Regulatory, Quality and Clinical Affairs for Atossa Genetics (NASDAQ: ATOS), a clinical-stage pharmaceutical company developing novel therapeutics and delivery methods for breast cancer and other breast conditions, will present on February 15th, 2018 at 4:15 PM as part of the Adoptive T- Cell Therapy Symposium at the Hilton San Francisco Union Square in San Francisco, CA. (213-3)

Atossa Genetics: Wait And See

2018-02-11 seekingalpha
Atossa Genetics (NASDAQ:ATOS) has moved into the news to start the new year with their announcement of Phase I data for their topical breast cancer drug Endoxifen, a metabolite of widely used tamoxifen, which was previously made by AstraZeneca (AZN). Between this compound's progress and the advanced trials for their micro-catheter device, the company is looking to move in new directions for the treatment of breast cancer. (195-4)

Vista Partners Updates Coverage on Four Dow 30 Companies: CAT, 3M, IBM & UNH

2018-02-09 accesswire
SAN FRANCISCO, CA / ACCESSWIRE / February 8, 2018 / Vista Partners ("Vista") has published updated coverage on four Dow 30 components 3M (MMM), Caterpillar (CAT), IBM (IBM) & UnitedHealth Group (UNH). The reports may be downloaded for FREE at the Vista Partners Coverage Section. (231-0)

ATOS / Atossa Genetics Inc 8-K (Current Report)

2018-02-02 sec.gov
  UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934   Date of Report (Date of Earliest Event Reported): February 1, 2018   Atossa Genetics Inc. (Exact name of registrant as specified in its charter)   Delaware   001-35610   26-4753208 (State or other jurisdiction of incorporation)   (Commission File Number)   (I.

Atossa Genetics Presents Additional Findings in Breast Cancer Study - Shares Up in After Hours Trading

2018-02-02 accesswire
SAN FRANCISCO, CA / ACCESSWIRE / February 1, 2018 / Atossa Genetics Inc. (NASDAQ: ATOS), a clinical-stage pharmaceutical company developing novel therapeutics and delivery methods to treat breast cancer and other breast conditions, announced additional findings from its Phase 1 study of Atossa's proprietary oral Endoxifen after the market closed today. Endoxifen is an active metabolite of the FDA-approved drug tamoxifen, which is currently used to treat breast cancer and for breast cancer prevention in high-risk patients. (195-0)

"Déjà vu All Over Again?"

2018-01-31 accesswire
SAN FRANCISCO, CA / ACCESSWIRE / January 31, 2018 / Vista Partners ("Vista") has published January's FREE Macroeconomic & Investment Monthly Newsletter, "Déjà vu All Over Again?". (211-0)

Atossa Genetics Receives Additional Sell Side Support & Coverage - Shares Surge

2018-01-26 accesswire
SAN FRANCISO, CA / ACCESSWIRE / January 26, 2018 / Seattle based Atossa Genetics Inc. (NASDAQ: ATOS) is a clinical-stage drug company developing novel, proprietary therapeutics and delivery methods for breast cancer and other breast conditions. They believe their innovative therapies and delivery methods can transform breast cancer treatment. (213-3)

3 FREE Biotech/Healthcare Research Reports: Atossa Genetics Inc. (ATOS), Johnson & Johnson, Inc. (JNJ), & Pfizer Inc. (PFE)

2018-01-23 accesswire
SAN FRANCISCO, CA / ACCESSWIRE / January 23, 2018 / All three reports are available for FREE at the Vista Partners Coverage Page. (211-1)

Stocks To Watch: Earnings Season Hits Higher Gear

2018-01-20 seekingalpha
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. (828-8)

ATOS / Atossa Genetics Inc / Empery Asset Management, LP - EMPERY ASSET MANAGEMENT, LP (Passive Investment)

2018-01-19 sec.gov
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549     SCHEDULE 13G     Under the Securities Exchange Act of 1934   (Amendment No. 1)*   Atossa Genetics Inc. (Name of Issuer)   Common Stock, $0.015 par value (Title of Class of Securities)   04962H209 (CUSIP Number)   December 31, 2017 (Date of event which requires filing of this statement)     Check the appropriate box to designate the rule pursuant to which this Schedule 13G is filed:   ¨ Rule 13d-1(b) x Rule 13d-1(c) ¨ Rule 13d-1(d)   (

ATOS / Atossa Genetics Inc / Empery Asset Management, LP - EMPERY ASSET MANAGEMENT, LP (Passive Investment)

2018-01-19 sec.gov
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549     SCHEDULE 13G     Under the Securities Exchange Act of 1934   (Amendment No. 1)*   Atossa Genetics Inc. (Name of Issuer)   Common Stock, $0.015 par value (Title of Class of Securities)   04962H209 (CUSIP Number)   December 31, 2017 (Date of event which requires filing of this statement)     Check the appropriate box to designate the rule pursuant to which this Schedule 13G is filed:   ¨ Rule 13d-1(b) x Rule 13d-1(c) ¨ Rule 13d-1(d)   (


ATOS : Atossa Genetics Stock Analysis and Research Report

Atossa Genetics is a clinical-stage pharmaceutical company focused on developing novel, proprietary therapeutics and delivery methods for the treatment of breast cancer and other breast conditions. The company currently have three programs underway: two using its proprietary endoxifen (oral and topical formulations) and the other using its patented microcatheter technology. The company's proprietary oral and topical forms of endoxifen are the subject of a comprehensive Phase 1 clinical study in healthy women in Australia. The company's patented microcatheter technology is in a Phase 2 clinical study that is also currently enrolling patients.

Approximately one in eight women will be diagnosed with breast cancer during their lifetime. Every two minutes an American woman is diagnosed with breast cancer; 40,000 die each year. Tamoxifen has been widely used for over 30 years to both treat and prevent breast cancer. Additional research has shown that it is the metabolites of tamoxifen, o...

Click for full article
CUSIP: 04962H100